tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Borro JM et al. Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome. 2007 Transplant. Proc. pmid:17889206
Loinaz C et al. A single-centre experience with cyclosporine microemulsion versus tacrolimus in 100 randomized liver transplant recipients: midterm efficacy and safety. 2001 Nov-Dec Transplant. Proc. pmid:11750472
Tolba RH et al. Conversion to Neoral for tacrolimus-related adverse effects in liver transplant recipients and improvement in quality of life. 2001 Nov-Dec Transplant. Proc. pmid:11750475
Rostaing L et al. Early posttransplantation renal hemodynamics in FK 506-treated kidney recipients with or without prior induction therapy. 1998 Transplant. Proc. pmid:9636519
Perrakis A et al. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome. 2011 Transplant. Proc. pmid:22172830
Rostaing L et al. Influence of early FK 506 trough levels on glomerular hemodynamics at 3 months in kidney transplant recipients. 1998 Transplant. Proc. pmid:9636520
Morris RE et al. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. 1990 Transplant. Proc. pmid:1689885
Todo S et al. Early trials with FK 506 as primary treatment in liver transplantation. 1990 Transplant. Proc. pmid:1689886
Sancho Calabuig A et al. Very low-grade proteinuria at 3 months posttransplantation is an earlier marker of graft survival. 2009 Jul-Aug Transplant. Proc. pmid:19715850
Kinoshita I et al. Immunosuppression with FK 506 insures good success of myoblast transplantation in MDX mice. 1994 Transplant. Proc. pmid:7527978
Reggiani P et al. Conversion to rescue therapy with FK 506: data from eight liver transplant patients. 1994 Transplant. Proc. pmid:7527982
Porayko MK et al. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients. 1993 Transplant. Proc. pmid:7679835
Goto Y et al. Outcome of tacrolimus-treated renal transplantation from elderly donors. 2000 Transplant. Proc. pmid:11119908
Shapiro R et al. Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. 1993 Transplant. Proc. pmid:7679836
Andersson J et al. FK 506 and cyclosporine inhibit antigen- or mitogen-induced monokine and lymphokine production in vitro. 1992 Transplant. Proc. pmid:1371621
Kay JE et al. Uptake of FK 506 by lymphocytes and erythrocytes. 1991 Transplant. Proc. pmid:1721269
Matsuura T et al. Blockade of interleukin-2 production from cloned T cells by cyclosporine and FK 506 assessed by proliferation assays in vitro. 1992 Transplant. Proc. pmid:1371623
Takada S et al. HGF prevents tacrolimus (FK 506)-induced nephrotoxicity in SHR rats. 1996 Transplant. Proc. pmid:8623236
Nakai T et al. Immunosuppressive mechanism and immune tolerance of FK 506 in rat small bowel transplantation. 1996 Transplant. Proc. pmid:8623237
Ciancio G et al. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. 2003 Transplant. Proc. pmid:12644172
Cofan F et al. Oxidation of low-density lipoproteins in renal transplant recipients treated with tacrolimus. 2002 Transplant. Proc. pmid:11959335
Burkhalter F et al. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study. 2012 Transplant. Proc. pmid:23195006
Steinmueller T et al. Effect of CsA versus FK 506 on insulin sensitivity and insulin response using a modeling technique. 1998 Transplant. Proc. pmid:9636589
Miura S et al. The beneficial effects of FK 506 on living-related renal transplantation in presensitized recipients. 1999 Transplant. Proc. pmid:10455940
Ringe B et al. Replacement of corticosteroids by mycophenolate mofetil in liver graft recipients on initial tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11120285
Watanabe K et al. Donor bone marrow cell infusion is effective in inducing tolerance in dogs treated with fractionated lymphoid irradiation and FK506. 2000 Transplant. Proc. pmid:11120286
Alloway RR et al. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. 1996 Transplant. Proc. pmid:8623494
Dumont FJ et al. Up-regulation of gene expression by FK 506. 1991 Transplant. Proc. pmid:1721300
Woodle ES et al. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. 1996 Transplant. Proc. pmid:8623495
Rao P et al. Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. 1991 Transplant. Proc. pmid:1721301
Koefoed-Nielsen PB et al. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients. 2005 Transplant. Proc. pmid:15919449
Kusne S et al. Infectious complications after small bowel transplantation in adults. 1994 Transplant. Proc. pmid:7518153
Iwahori T et al. Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. 2005 Transplant. Proc. pmid:15919450
Kitamura T et al. Severe hemolytic anemia related to production of cold agglutinins following living donor liver transplantation: a case report. 2003 Transplant. Proc. pmid:12591458
Masutani H et al. Suppression of the histologic changes of GVHD by FK 506 in rat small bowel transplantation. 1992 Transplant. Proc. pmid:1376519
Wennberg L et al. Efficacy of various immunosuppressive drugs in preventing pig-to-rat islet xenograft rejection. 1995 Transplant. Proc. pmid:7533391
Fung J et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. 1991 Transplant. Proc. pmid:1721333
Lladó L et al. Prospective study of a tacrolimus-based quadruple immunosuppressive regimen: evaluation of safety and efficacy. 2002 Transplant. Proc. pmid:12176468
Serrano J et al. Tacrolimus is effective in both dual and triple regimens after liver transplantation. 2002 Transplant. Proc. pmid:12176469
Fleck PR et al. Tacrolimus use in kidney-pancreas recipients is associated with less acute renal dysfunction than cyclosporine. 1998 Transplant. Proc. pmid:9865299
du Toit DF et al. Tacrolimus (FK506) monotherapy provides potent and significant suppression of allogeneic foetal rat pancreatic allograft rejection. 1998 Transplant. Proc. pmid:9865300
Niel OR et al. Long-term glomerular filtration rate in liver allograft recipients according to the type of calcineurin inhibitors. 2009 Transplant. Proc. pmid:19857743
Jacques F et al. Comparison of cyclosporine and tacrolimus in combination with rabbit antithymocyte immunoglobulins as induction therapy in cardiac transplantation. 2009 Transplant. Proc. pmid:19857745
Regazzi MB et al. Pharmacokinetics of FK506 and mycophenolic acid in experimental and clinical intestinal transplantation. 1997 Transplant. Proc. pmid:9142302
Hansen LJ et al. Early pharmacokinetic profiles of enteral tacrolimus after multivisceral transplantation. 1997 Transplant. Proc. pmid:9142303
Oltean M et al. FK506 donor pretreatment improves intestinal graft microcirculation and morphology by concurrent inhibition of early NF-kappaB activation and augmented HSP72 synthesis. 2005 Transplant. Proc. pmid:15919508
Lemster B et al. Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. 1992 Transplant. Proc. pmid:1281576
Tze WJ et al. FK 506: an effective immunosuppressant for islet xenotransplantation. 1992 Transplant. Proc. pmid:1281577
Jensen CW et al. Pediatric renal transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721364
Jordan ML et al. FK 506 conversion of renal allografts failing cyclosporine immunosuppression. 1991 Transplant. Proc. pmid:1721365
Pascual J et al. Comparison between a two-drug regimen with tacrolimus and steroids and a triple one with azathioprine in kidney transplantation: results of a European trial with 3-year follow up. 2003 Transplant. Proc. pmid:12962764
Charpentier B A three arm study comparing immediate tacrolimus therapy with ATG induction therapy followed by either tacrolimus or cyclosporine in adult renal transplant recipients. 2002 Transplant. Proc. pmid:12176511
Choi JY and Kwon OJ Post-transplant diabetes mellitus: is it associated with poor allograft outcomes in renal transplants? 2013 Transplant. Proc. pmid:24156999
Soylu H et al. Survival of renal transplant patients: data from a tertiary care center in Turkey. 2015 Transplant. Proc. pmid:25769571
Watanabe K et al. Prolongation effect of FK506 on the survival of 3-day preserved kidney allografts in dogs. 1998 Transplant. Proc. pmid:9838579
Mueller AR et al. Is the use of marginal liver grafts justified? 1999 Feb-Mar Transplant. Proc. pmid:10083160
Karakulska-Prystupiuk E et al. Pericarditis in Patients With Chronic Graft-vs-Host Disease. 2018 Transplant. Proc. pmid:30177139
Kusne S et al. Early infections in kidney transplant recipients under FK 506. 1991 Transplant. Proc. pmid:1703364
Takeuchi H et al. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level. 2008 Transplant. Proc. pmid:18790203
Shimizu T et al. Clinical and histological analysis of chronic tacrolimus nephrotoxicity in renal allografts. 2008 Transplant. Proc. pmid:18790237
Zipperle S et al. Impaired T-cell IL-10 secretion and CD4 helper function in liver transplant patients treated with tacrolimus. 1997 Feb-Mar Transplant. Proc. pmid:9123208
Freise CE et al. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. 1991 Transplant. Proc. pmid:1721397
McGrath JS and Shehata M The effect of differing immunosuppressive regimes on the functional and morphologic changes in a rat renal allograft model of chronic rejection. 2001 Transplant. Proc. pmid:11377499
Koefoed-Nielsen PB and Jørgensen KA Alterations in calcineurin phosphatase activity in tacrolimus-treated renal transplant patients. 2002 Transplant. Proc. pmid:12176559
McGrath JS and Shehata M Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution. 2001 Transplant. Proc. pmid:11377500
Baid S et al. Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: role of hepatitis C infection. 2002 Transplant. Proc. pmid:12176569
Gasser M et al. Putative regulatory function of alloreactive Th2 cells in tolerant recipients after small bowel transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11266759
Nakao A et al. Changes of allo-intestinal graft survival and intragraft cytokine expression by bone marrow augmentation with tacrolimus treatment in rats. 2001 Feb-Mar Transplant. Proc. pmid:11266851
Jiang H et al. Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. 1999 Feb-Mar Transplant. Proc. pmid:10083538
Hoshino Y et al. FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models. 1999 Feb-Mar Transplant. Proc. pmid:10083547
Kahan BD High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection. 1998 Transplant. Proc. pmid:9723224
Keown PA and Primmett DR Cyclosporine: the principal immunosuppressant for renal transplantation. 1998 Transplant. Proc. pmid:9723252
Yamada MF et al. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis. 2008 Transplant. Proc. pmid:19100456
Lauro A et al. Liver transplantation for familial amyloid polyneuropathy non-VAL30MET variants: are cardiac complications influenced by prophylactic pacing and immunosuppressive weaning? 2005 Transplant. Proc. pmid:15964382
Jiménez-Pérez M et al. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation. Transplant. Proc. pmid:25645779
Zucker MJ et al. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis. 2005 Transplant. Proc. pmid:15964386
Polanco N et al. Everolimus-based immunosuppression therapy for BK virus nephropathy. Transplant. Proc. pmid:25645770
Ogasa N et al. Effect of FK 506 on growth of transplanted newborn rat intestine. 1991 Transplant. Proc. pmid:1721428
Kakefuda T et al. Detection of nitrosylhemoglobin in liver allograft in rats by using near-infrared spectroscopy. 1996 Transplant. Proc. pmid:8658885
MacDonald AS Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. 2003 Transplant. Proc. pmid:12742497
Sindhi R et al. Pharmacodynamics of sirolimus in transplanted children receiving tacrolimus. 2002 Transplant. Proc. pmid:12176644
Chakrabarti P et al. Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267274
Grabczewska Z et al. Neither cyclosporine nor tacrolimus deteriorate endothelial function in renal transplant recipients assessed with reactive hyperernia index. 2013 Transplant. Proc. pmid:23726621
Thiru S et al. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK-506. 1987 Transplant. Proc. pmid:2445086
Xu M et al. FTY720 compares with FK 506 as rescue therapy in rat heterotopic cardiac transplantation. 1998 Transplant. Proc. pmid:9723447
Maroun T et al. Rejection therapy with tacrolimus in renal transplantation: preliminary results of a collaborative multicenter study in 45 patients. Groupe Cooperatif de Transplantation D'ile de France (GCIF). 1998 Transplant. Proc. pmid:9745576
Pirsch JD Mycophenolate mofetil, tacrolimus, Neoral: from clinical trials to the clinic. 1998 Transplant. Proc. pmid:9723448
Martín-Fernández M et al. Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts. 2017 Transplant. Proc. pmid:29149986
Antoine C et al. Vascular microthrombosis in renal transplant recipients treated with tacrolimus. 1998 Transplant. Proc. pmid:9745577
Fung JJ and Starzl TE FK 506 in solid organ transplantation. 1994 Transplant. Proc. pmid:7524226
McCauley J et al. FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. 1991 Transplant. Proc. pmid:1721459
Carrieri G et al. Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. 1991 Transplant. Proc. pmid:1721460
Griffin AD et al. FK 506 in canine renal transplantation. 1992 Transplant. Proc. pmid:1384209
Iwata H et al. Prolongation of xenograft survival by combining donor-specific intravenous presensitization with FK 506. 2002 Transplant. Proc. pmid:12431592
Molmenti EP et al. Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267487
Wojarski J et al. Immunosuppressive Treatment and Its Effect on the Occurrence of Pneumocystis jiroveci, Mycoplasma pneumoniae, Chlamydophila pnemoniae, and Legionella pneumophila Infections/Colonizations Among Lung Transplant Recipients. 2018 Transplant. Proc. pmid:30177108
Marcus N et al. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients. 1998 Transplant. Proc. pmid:9636460
Filler G Optimization of immunosuppressive drug monitoring in children. 2007 Transplant. Proc. pmid:17524944
Halim MA et al. De novo Crohn's disease in a renal transplant recipient. 2007 Transplant. Proc. pmid:17524953
Ericzon BG et al. Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. 1991 Transplant. Proc. pmid:1703695